Search Press releases Keywords From To 5 Jun 2026 New EULAR 2026 data show CIMZIA[®] (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels Read More 4 Jun 2026 EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus Read More 3 Jun 2026 BIMZELX[®](bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA Read More 2 Jun 2026 UCB completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science Read More 2 Jun 2026 UCB presents research at EUROMIT 2026 highlighting burden of care, need for earlier diagnosis, and impact of pyrimidine nucleoside therapy on people living with TK2d Read More 1 Jun 2026 UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 1 of 64 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
